Impact of highly active antiretroviral therapy on CD4+ T cells and viral load of children with AIDS: A population-based study

AIDS Research and Human Retroviruses

Volumn 20, Issue 9, 2004, Pages 927-931

  Resino, Salvador ^a   Bellón, José M ^a   Ramos, José Tomas ^b   Resino, Rosa ^a   Gurbindo, M Dolores ^a   Mellado, M José ^c   De José, M Isabel ^c   Muñoz Fernández, M Ángeles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD;

EID: 5644254527     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2004.20.927     Document Type: Article

References (31)

1. CDCP: Guidelines for use of antiviral agents in pediatric HIV infection. MMWR 1998;47:1-43.
2. Sharland M, Gibb D, and Giaquinto C: Current evidence for use of paediatric antiretroviral therapy-a PENTA analysis. Pediatric European Network for the Treatment of AIDS Steering Committee. Eur J Pediatr 2000;159(9):649-656.
3. Mueller BU, Sleasman J, Nelson RP, Jr, Smith S, Deutsch PJ, Ju W, et al.: A phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics 1998;102(1):e8.
4. Rutstein RM, Feingold A, Meislich D, Word B, and Rudy B: Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS 1997;11:F107-111.
5. Krogstad P, Wiznia A, Luzuriaga K, Dankner W, Nielsen K, Gersten M, et al.: Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis 1999;28(5):1109-1118.
6. Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, et al.: Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med 1999;34(25):1874-1881.
7. + T-cells response to HAART in HIV-infected children: An observational study. Clin Infect Dis 2003;37:1216-1225.
8. Resino S, Bellón J, Gurbindo D, and Muñoz-Fernández MA: CD38 in CD8+ T cells predict virological failure in HIV-infected children receiving antiretroviral therapy. Clin Infect Dis 2004;38(3):412-417.
9. Sharland M, di Zub GC, Ramos JT, Blanche S, and Gibb DM: PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. Pediatric European Network for Treatment of AIDS. HIV Med 2002;3(3):215-226.
10. CDCP: Revised classification system for HIV-1 infection in children less than 13 years of age. MMWR CDC Surveill Summ 1994;43(RR-12):1-10.
11. Munoz-Fernandez MA, Obregon E, Navarro J, Borner C, Gurbindo MD, Sampelayo TH, et al.: Relationship of virological, immunologic, and clinical parameters in infants with vertically acquired human immunodeficiency virus type 1 infection. Pediatr Res 1996;40(4):597-602.
12. Resino S, Gurbindo M, Bellon J, Sanchez-Ramon S, and Muñoz- Fernández M: Predictive markers of clinical outcome in vertically HIV-1 infected infants. A prospective longitudinal study. Pediatr Res 2000;47(4):509-515.
13. Moore RD: Cost effectiveness of combination HIV therapy: 3 years later. Pharmacoeconomics 2000;17(4):325-330.
14. Munoz A, Gange SJ, and Jacobson LP: Distinguishing efficacy, individual effectiveness and population effectiveness of therapies. AIDS 2000;14(6):754-756.
15. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al.: Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280(17):1497-1503.
16. Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, and Munoz A: Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001;15(3):347-355.
17. Jacobson LP, Li R, Phair J, Margolick JB, Rinaldo CR, Detels R, et al:. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression. Am J Epidemiol 2002;155(8):760-770.
18. Resino S, Bellón J, Resino R, Navarro M, Ramos J, Mellado M, et al:. Extensive implementation of highly active antiretroviral therapy shows great effectiveness on the survival and surrogate markers in vertically HIV-infected children. Clin Infect Dis 2004;38(11):1605-1612.
19. de Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rezza G, et al.: Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 2000;284(2):190-197.
20. Wintergerst U, Hoffmann F, Solder B, Notheis G, Petropoulou T, Eberle J, et al.: Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus. Pediatr Infect Dis J 1998; 17(6):517-518.
21. PENTA: Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: The PENTA 5 randomised trial. Lancet 2002;359(9308):733-740.
22. van Rossum AM, Niesters HG, Geelen SP, Scherpbier HJ, Hartwig NG, Weemaes CM, et al.: Clinical and virologie response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: A Multicenter study in the Netherlands. On behalf of the Dutch Study Group for Children with HIV-1 infections. J Pediatr 2000; 136(6):780-788.
23. Resino S, Correa R, Bellon J, Sanchez-Ramon S, and Muñoz-Fernandez M: Characterizing immune reconstitution after long-term HAART in pediatric AIDS. AIDS Res Hum Retroviruses 2002;18(18):1395-1406.
24. Borkowsky W, Stanley K, Douglas SD, Lee S, Wiznia A, Pelton S, et al.: Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children. J Infect Dis 2000;182(1):96-103.
25. van Rossum AM, Bergshoeff AS, Fraaij PL, Hugen PW, Hartwig NG, Geelen SP, et al.: Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002;21(8): 743-747.
26. Purswani M, Johann-Liang R, Cervia J, and Noel GJ: Effect of changing antiretroviral therapy on human immunodeficiency virus viral load: Experience with fifty-four perinatally infected children. Lancet 1999;353(9171):2240.
27. Resino S, Bellón JM, Gurbindo D, Ramos JT, Leon JA, and Muñoz-Fernández MA: Dynamics of progression markers in a non-study population of HIV-1 vertically infected with different antiretroviral treatments. Acta Paediatr 2002;91:776-782.
28. Resino S, Bellon JM, Sanchez-Ramon S, Gurbindo D, Ruiz-Contreras J, Leon JA, et al.: Impact of antiretroviral protocols on dynamics of AIDS progression markers. Arch Dis Child 2002; 86(2):119-124.
29. Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, Almy S, et al.: Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 1997;336(19):1337-1342.
30. Resino S, Galán I, Bellón JM, Navarro M, León JA, and Muñoz-Fernández MA: Characterising the immune system after long-term undetectable viral load in HIV-1-infected children. J Clin Immunol 2003;23(4):279-289.
31. Melvin AJ, Mohan KM, Arcuino LA, Edelstein RE, and Frenkel LM: Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. Clin Exp Immunol 1997; 110(1):15-21.